What is Zacks Research’s Estimate for TEVA Q3 Earnings?

Teva Pharmaceutical Industries Limited (NYSE:TEVA) – Analysts at Zacks Research increased their Q3 2025 earnings estimates for shares of Teva Pharmaceutical Industries in a research report issued to clients and investors on Monday, November 4th. Zacks Research analyst R. Department now anticipates that the company will earn $0.67 per share for the quarter, up from their previous forecast of $0.66. The consensus estimate for Teva Pharmaceutical Industries’ current full-year earnings is $2.33 per share. Zacks Research also issued estimates for Teva Pharmaceutical Industries’ FY2025 earnings at $2.55 EPS and Q2 2026 earnings at $0.61 EPS.

Several other brokerages also recently weighed in on TEVA. JPMorgan Chase & Co. upped their target price on Teva Pharmaceutical Industries from $16.00 to $18.00 and gave the stock a “neutral” rating in a research note on Monday, October 21st. StockNews.com upgraded shares of Teva Pharmaceutical Industries from a “buy” rating to a “strong-buy” rating in a research report on Thursday, October 17th. Barclays lifted their target price on shares of Teva Pharmaceutical Industries from $22.00 to $25.00 and gave the company an “overweight” rating in a research report on Wednesday, October 23rd. Argus raised shares of Teva Pharmaceutical Industries from a “hold” rating to a “buy” rating and set a $20.00 target price for the company in a research note on Wednesday, July 10th. Finally, UBS Group raised their price target on shares of Teva Pharmaceutical Industries from $24.00 to $26.00 and gave the company a “buy” rating in a research note on Tuesday, September 3rd. Two research analysts have rated the stock with a hold rating, seven have issued a buy rating and one has assigned a strong buy rating to the stock. According to data from MarketBeat, Teva Pharmaceutical Industries presently has an average rating of “Moderate Buy” and a consensus price target of $19.67.

Teva Pharmaceutical Industries Stock Performance

NYSE TEVA opened at $18.78 on Wednesday. The stock has a 50-day moving average of $18.03 and a 200 day moving average of $17.06. The company has a quick ratio of 0.59, a current ratio of 0.89 and a debt-to-equity ratio of 2.52. Teva Pharmaceutical Industries has a twelve month low of $8.55 and a twelve month high of $19.08.

Hedge Funds Weigh In On Teva Pharmaceutical Industries

A number of institutional investors and hedge funds have recently added to or reduced their stakes in TEVA. New Covenant Trust Company N.A. acquired a new position in Teva Pharmaceutical Industries in the 1st quarter valued at about $28,000. EntryPoint Capital LLC acquired a new position in Teva Pharmaceutical Industries in the first quarter valued at approximately $30,000. UMB Bank n.a. grew its position in Teva Pharmaceutical Industries by 555.6% in the third quarter. UMB Bank n.a. now owns 2,439 shares of the company’s stock worth $44,000 after acquiring an additional 2,067 shares during the period. Beach Investment Counsel Inc. PA acquired a new stake in Teva Pharmaceutical Industries during the second quarter worth $48,000. Finally, Byrne Asset Management LLC acquired a new stake in Teva Pharmaceutical Industries during the second quarter worth $52,000. Institutional investors and hedge funds own 54.05% of the company’s stock.

About Teva Pharmaceutical Industries

Teva Pharmaceutical Industries Limited develops, manufactures, markets, and distributes generic medicines, specialty medicines, and biopharmaceutical products in North America, Europe, Israel, and internationally. It offers generic medicines in various dosage forms, such as tablets, capsules, injectables, inhalants, liquids, transdermal patches, ointments, and creams; sterile products, hormones, high-potency drugs, and cytotoxic substances in parenteral and solid dosage forms; and generic products with medical devices and combination products.